Q-omics provides the consensus-scored PAK5 profile across patient tissues and cancer cell-line models. PAK5 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PAK5 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, PAK5 protein abundance shows 29,946 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where PAK5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PAK5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PAK5 survival associations across molecular data types. PAK5 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (7) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PAK5 RNA expression–survival associations across cancer types. High PAK5 expression shows unfavorable associations in LIHC and KIRC, but favorable associations in ACC, BRCA, LGG and UCS. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PAK5 RNA expression.
This table summarizes PAK5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PAK5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PAK5 shows lower tumor expression in KIRC, LUAD, KIRP, THCA and BRCA and higher tumor expression in LUSC. The KIRC box plot shows higher PAK5 RNA expression in normal versus tumor tissue (log2 FC = −0.587, t-test p < 0.001).
This table shows molecular features associated with PAK5 in patient tissues and cancer cell lines. In patient samples, PAK5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PAK5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
